ES2656623T3 - Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma - Google Patents

Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma Download PDF

Info

Publication number
ES2656623T3
ES2656623T3 ES13817593.0T ES13817593T ES2656623T3 ES 2656623 T3 ES2656623 T3 ES 2656623T3 ES 13817593 T ES13817593 T ES 13817593T ES 2656623 T3 ES2656623 T3 ES 2656623T3
Authority
ES
Spain
Prior art keywords
dimaleate
crystalline form
tyrosine kinase
kinase inhibitor
preparation methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13817593.0T
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Bo Yuan
Yongjiang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Application granted granted Critical
Publication of ES2656623T3 publication Critical patent/ES2656623T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forma cristalina I de dimaleato de (R,E)-N-(4-(3-cloro-4-(piridin-2-ilmetoxi)-fenilamino)-3-ciano-7-etoxiquinolin-6-il)- 3-(1-metilpirrolidin-2-il)acrilamida, caracterizada por que se usa radiación Kα de Cu para obtener los patrones de difracción de rayos X representados por ángulos 2θ y distancia de cristal interplanar, teniendo el cristal patrones de difracción de rayos X como se muestra en la Figura 1 en la que hay picos característicos en 6,28(14,06), 6,74(13,10), 10,60(8,34), 11,58(7,64), 13,50(6,55), 14,90(5,94), 15,80(5,60), 18,26(4,85), 20,66(4,30), 21,14(4,20), 22,96(3,87), 24,34(3,65), 25,54(3,49) y 26,12(3,41).

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES13817593.0T 2012-07-12 2013-06-04 Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma Active ES2656623T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210240697.0A CN103539783A (zh) 2012-07-12 2012-07-12 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN201210240697 2012-07-12
PCT/CN2013/076717 WO2014008794A1 (zh) 2012-07-12 2013-06-04 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Publications (1)

Publication Number Publication Date
ES2656623T3 true ES2656623T3 (es) 2018-02-27

Family

ID=49915377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13817593.0T Active ES2656623T3 (es) 2012-07-12 2013-06-04 Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma

Country Status (20)

Country Link
US (1) US9309226B2 (es)
EP (1) EP2873664B1 (es)
JP (1) JP6170146B2 (es)
KR (1) KR102078077B1 (es)
CN (2) CN103539783A (es)
AU (1) AU2013289789B2 (es)
BR (1) BR112015000045B1 (es)
CA (1) CA2876884C (es)
DK (1) DK2873664T3 (es)
ES (1) ES2656623T3 (es)
HU (1) HUE037946T2 (es)
MX (1) MX349672B (es)
NO (1) NO2873664T3 (es)
PL (1) PL2873664T3 (es)
PT (1) PT2873664T (es)
RU (1) RU2631321C2 (es)
TW (1) TWI597277B (es)
UA (1) UA113658C2 (es)
WO (1) WO2014008794A1 (es)
ZA (1) ZA201500471B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985408B (zh) * 2015-02-12 2020-06-26 正大天晴药业集团股份有限公司 一种卡非佐米的纯化方法
CN108026059A (zh) 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
CA3008701A1 (en) 2016-01-27 2017-08-03 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
CN108354909B (zh) * 2016-01-27 2021-05-14 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
WO2017129094A1 (zh) * 2016-01-28 2017-08-03 江苏恒瑞医药股份有限公司 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
CA3016092C (en) * 2016-03-22 2025-03-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. POLYCRYSTALLINE FORM OF FREE BASIC OR SALT EGFR INHIBITOR ACID, PROCESS FOR ITS PREPARATION AND APPLICATION
CN113769097A (zh) 2017-01-22 2021-12-10 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2019029477A1 (zh) * 2017-08-07 2019-02-14 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法
CN109516976B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法
CA3079916A1 (en) 2017-10-24 2019-05-02 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing quinoline derivative
CN110960529A (zh) * 2018-09-30 2020-04-07 江苏恒瑞医药股份有限公司 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药
MX2021004600A (es) 2018-10-22 2021-06-15 Jiangsu Hengrui Medicine Co Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo.
CN111138414A (zh) * 2018-11-05 2020-05-12 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的晶型及其制备方法
WO2021037185A1 (zh) * 2019-08-30 2021-03-04 江苏恒瑞医药股份有限公司 一种低杂质含量的酪氨酸激酶抑制剂
CN114674937B (zh) * 2020-12-24 2024-07-05 沈阳药科大学 一种马来酸长链脂肪酰胺中长链脂肪胺的测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
UA113658C2 (xx) 2017-02-27
EP2873664A1 (en) 2015-05-20
CA2876884C (en) 2019-12-10
JP2015522042A (ja) 2015-08-03
HK1199027A1 (zh) 2015-06-19
AU2013289789A1 (en) 2015-01-22
EP2873664B1 (en) 2017-11-01
CN103974949B (zh) 2015-11-25
CN103539783A (zh) 2014-01-29
US9309226B2 (en) 2016-04-12
KR20150036336A (ko) 2015-04-07
KR102078077B1 (ko) 2020-02-17
MX349672B (es) 2017-08-08
RU2631321C2 (ru) 2017-09-21
MX2014015623A (es) 2015-06-23
US20150166511A1 (en) 2015-06-18
TWI597277B (zh) 2017-09-01
JP6170146B2 (ja) 2017-07-26
ZA201500471B (en) 2016-10-26
BR112015000045B1 (pt) 2021-10-26
NO2873664T3 (es) 2018-03-31
PT2873664T (pt) 2018-01-24
CA2876884A1 (en) 2014-01-16
CN103974949A (zh) 2014-08-06
BR112015000045A2 (pt) 2017-06-27
EP2873664A4 (en) 2015-12-30
TW201402563A (zh) 2014-01-16
RU2015103065A (ru) 2016-08-27
AU2013289789B2 (en) 2017-06-29
DK2873664T3 (en) 2018-01-08
PL2873664T3 (pl) 2018-06-29
HUE037946T2 (hu) 2018-09-28
WO2014008794A1 (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
ES2656623T3 (es) Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
PE20140002A1 (es) Proceso de elaboracion para derivados de pirimidina
RU2016146119A (ru) Новый кристалл тетрациклического соединения
RU2019100065A (ru) Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
BR112015019627A2 (pt) amidas heterocíclicas como inibidores de quinases
PY1432622A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
EA201792355A1 (ru) Способ получения противоракового средства 1-((4-(4-фтор-2-метил-1h-индол-5-илокси)-6-метоксихинолин-7-илокси)метил)циклопропанамина, его кристаллической формы и солей
EA201591913A1 (ru) Ингибиторы протеинкиназы
RU2015112098A (ru) Кристаллы производных диспиропирролидина
UA129695C2 (uk) Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
PE20141061A1 (es) Compuesto inhibidor de la senalizacion de la trayectoria notch
UA116920C2 (uk) Інгібітори fgfr4
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
EP3365344A4 (en) SALT OF EGFR INHIBITOR, CRYSTALLINE FORM AND USES THEREOF
RU2018119102A (ru) Терапевтическое средство для лечения рака молочной железы
CY1119581T1 (el) Παραγωγα πυριδινυλο- και πυραζινυλο-μεθυλοξυ-αρυλιου χρησιμα ως αναστολεις της τυροσινης κινασης σπληνας (syk)
EA201591530A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
LT2925324T (lt) Trans-4-{2-[4-(2,3-dichlorfenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilaminas, skirtas pirminių neigiamų šizofrenijos simptomų gydymui
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.